Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Neuroendocrine × Everolimus × Clear all

Phase

Phase 2 9 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Carcinoma, Renal Cell 6 Hodgkin Disease 5 Glioblastoma 5 Colorectal Neoplasms 5 Central Nervous System Neoplasms 5 Waldenstrom Macroglobulinemia 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Lymphoma, Mantle-Cell 4 Head and Neck Neoplasms 4 Gliosarcoma 4 Tuberous Sclerosis 3 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Sezary Syndrome 3 Recurrence 3 Prostatic Neoplasms 3 Neoplasms 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Kidney Neoplasms 3

Interventions

atezolizumab 2 Etoposide 2 Cisplatin 2 veliparib 1 tivozanib 1 surufatinib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 durvalumab 1 berzosertib 1 avelumab 1 Topotecan 1 Podophyllotoxin 1 Platinum 1 Paclitaxel 1 Nivolumab 1 Ipilimumab 1 Everolimus 1 EC regimen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02205515 2022-08-19

EBRT

Sunnybrook Health Sciences Centre

Phase 1/2 Completed

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡